Otilimab
- Generic Name
- Otilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1638332-55-4
- Unique Ingredient Identifier
- Y8127R3VCH
- Background
Investigated for the treatment of osteoarthritis and rheumatoid arthritis (RA).
- Indication
Investigated for use/treatment in inflammatory disorders (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1156
- Registration Number
- NCT04376684
- Locations
- 🇬🇧
GSK Investigational Site, Liverpool, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath